Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belinostat Extension Study
NCT04184869Phase 1Completed
- Sponsor
- Acrotech Biopharma Inc
- Start
- Aug 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of belinostat in solid tumor and hematologic malignancy (4 arms), sponsored by Acrotech Biopharma Inc. Primary endpoints: Evaluation of safety including assessment of all Serious Adverse Events (SAEs) and Evaluation of safety including assessment of all deaths. Started Aug 2019; status: completed.
02
Drugs
belinostat
03
Conditions
solid tumorhematologic malignancy
Beyond the preview
Go deeper on NCT04184869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04184869.